Nkarta, Inc. (NASDAQ:NKTX) CEO Sells $38,231.60 in Stock

Nkarta, Inc. (NASDAQ:NKTX) CEO Paul J. Hastings sold 17,378 shares of the company’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total transaction of $38,231.60. Following the transaction, the chief executive officer now owns 319,859 shares of the company’s stock, valued at approximately $703,689.80. The trade was a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Nkarta Stock Performance

Shares of NASDAQ NKTX traded down $0.02 during trading on Friday, hitting $2.47. The company had a trading volume of 1,770,362 shares, compared to its average volume of 1,352,778. Nkarta, Inc. has a 12 month low of $2.08 and a 12 month high of $16.24. The firm has a market capitalization of $174.31 million, a P/E ratio of -1.31 and a beta of 0.85. The stock has a 50 day simple moving average of $2.54 and a 200 day simple moving average of $4.21.

Analysts Set New Price Targets

NKTX has been the subject of a number of research reports. HC Wainwright lowered their price objective on Nkarta from $22.00 to $18.00 and set a “buy” rating for the company in a research report on Monday, November 11th. RODMAN&RENSHAW raised shares of Nkarta to a “strong-buy” rating in a research report on Wednesday, October 9th. Needham & Company LLC lowered their price objective on shares of Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Friday, November 8th. Mizuho decreased their price target on shares of Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a research note on Thursday, November 21st. Finally, Rodman & Renshaw assumed coverage on shares of Nkarta in a research note on Wednesday, October 9th. They set a “buy” rating and a $14.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Nkarta currently has an average rating of “Buy” and a consensus price target of $15.00.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Erste Asset Management GmbH purchased a new stake in Nkarta during the 3rd quarter valued at about $33,000. GAMMA Investing LLC boosted its position in Nkarta by 110.9% during the third quarter. GAMMA Investing LLC now owns 9,972 shares of the company’s stock worth $45,000 after acquiring an additional 5,243 shares during the last quarter. Forefront Analytics LLC acquired a new stake in shares of Nkarta during the 2nd quarter worth approximately $70,000. Intech Investment Management LLC purchased a new stake in shares of Nkarta in the 3rd quarter valued at approximately $74,000. Finally, SG Americas Securities LLC acquired a new position in shares of Nkarta in the third quarter valued at approximately $93,000. Hedge funds and other institutional investors own 80.54% of the company’s stock.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.